Percutaneous Mitral Valve Repair for Mitral Regurgitation in High-Risk Patients
Results of the EVEREST II Study
Donald D. Glower, Saibal Kar, Alfredo Trento, D. Scott Lim, Tanvir Bajwa, Ramon Quesada, Patrick L. Whitlow, Michael J. Rinaldi, Paul Grayburn, Michael J. Mack, Laura Mauri, Patrick M. McCarthy and Ted Feldman
Symptoms of Heart Failure (NYHA Functional Class) at Baseline, 30 Days, and 12 Months After Percutaneous MitraClip Placement in High-Risk Patients
In high-risk patients with severe mitral regurgitation, percutaneous MitraClip therapy significantly improved New York Heart Association (NYHA) functional class at 30 days and at 12 months relative to baseline (p < 0.001).